Novartis headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)

No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

CHICA­GO — No­var­tis’ CDK4/6 in­hibitor Kisqali helped ear­ly breast can­cer pa­tients stay can­cer-free for longer af­ter surgery, ac­cord­ing to in­ter­im study re­sults pre­sent­ed at AS­CO.

In a Phase III study, Kisqali was added on top of en­docrine ther­a­py — the cur­rent stan­dard treat­ment for ear­ly breast can­cer pa­tients. Kisqali re­duced the risk of dis­ease re­lapse by 25% com­pared with en­docrine ther­a­py alone in pa­tients with Stage II or III HR-pos­i­tive, HER2-neg­a­tive breast can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.